Longevity & CellularEmerging

Pinealon

A neuroprotective peptide bioregulator that enhances cognitive function and supports aging brain health through MAPK/ERK signaling.

Also known as: EDR Tripeptide, Glu-Asp-Arg

SubcutaneousIntramuscularOral

Available on Forge Amino

Pinealon 20MG — independently lab tested, 99%+ purity, QR-linked COA.

Source this compound →

Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.

How It Works

Activates MAPK/ERK signaling in neurons, upregulating neuroprotective genes and BDNF. Suppresses apoptosis through caspase inhibition and ROS reduction.

Key Benefits

  • Enhanced memory acquisition and retention
  • Improved attention and concentration
  • Accelerated reaction time
  • Neuroprotection in aging
  • Potential brain injury recovery support

Dosing Protocols

Beginner / Intermediate

Dose

100 mcg

Frequency

Once daily subcutaneous

Cycle Length

6-8 weeks

Notes

Or 200-300 mg daily oral if bioavailable formulation used

Advanced

Dose

200-300 mcg

Frequency

Once daily subcutaneous

Cycle Length

8-12 weeks

Notes

Multiple courses per year; 2-4 week rest between cycles

Side Effects & Safety

Common Side Effects

  • Minimal reported; well-tolerated
  • Rare: injection site reactions
  • Anecdotal: muscle aches or fatigue
  • Generally safe with decades of Russian use

Contraindications

  • No formal contraindications established

Stacking & Synergies

These compounds have complementary mechanisms and may enhance results when used together.

NAD+ precursors (NMN)Magnesium L-ThreonateB-Complex vitaminsCognitive training

Key Takeaway

Preserve cognitive sharpness: Pinealon activates MAPK/ERK to upregulate neuroprotective genes.

Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.